On Jan. 31, 2012, the FDA approved a KALYDECO (ivacaftor), University of Washington-tested drug to treat the genetic mechanism of cystic fibrosis, the first of its kind. Kalydeco is manufactured by Vertex Pharmaceuticals of Cambridge, Mass.